Is expanded access to GLP-1 medicines hanging in the BALANCE as CMS delays its payment and coverage model? | Becaris Publishing

Is expanded access to GLP-1 medicines hanging in the BALANCE as CMS delays its payment and coverage model? | Becaris Publishing becarispublishing.com/digital-cont...

Perspectives from the Healthcare Economist: Two visions for value – Why GCEA and HEMA clash on drug pricing | Becaris Publishing

Perspectives from the Healthcare Economist: Two visions for value – Why GCEA and HEMA clash on drug pricing | Becaris Publishing becarispublishing.com/digital-cont...

A new framework for patient engagement in rare disease HTA: Rick Chapman and Michelle Cheng of IVI on the Rare Disease Patient Engagement Guidance and Checklist | Becaris Publishing

A new framework for patient engagement in rare disease HTA: Rick Chapman and Michelle Cheng of IVI on the Rare Disease Patient Engagement Guidance and Checklist | Becaris Publishing becarispublishing.com/digital-cont...

FDA shares insights on growing use of real-world evidence in medical device approvals | Becaris Publishing

FDA shares insights on growing use of real-world evidence in medical device approvals | Becaris Publishing becarispublishing.com/digital-cont...

Value Viewpoint: Prying open the pharmacy benefit manager black box to decode the 2026 PBM reforms | Becaris Publishing

Value Viewpoint: Prying open the pharmacy benefit manager black box to decode the 2026 PBM reforms | Becaris Publishing becarispublishing.com/digital-cont...

Can I trust agentic AI? Validating autonomous analytics for real-world data | Becaris Publishing

Can I trust agentic AI? Validating autonomous analytics for real-world data | Becaris Publishing becarispublishing.com/digital-cont...

EMA publishes final real world data chapter of EU Data Quality Framework | Becaris Publishing

EMA publishes final real world data chapter of EU Data Quality Framework | Becaris Publishing becarispublishing.com/digital-cont...

New ABPI report sets out plan to accelerate UK clinical trials using NHS data | Becaris Publishing

New ABPI report sets out plan to accelerate UK clinical trials using NHS data | Becaris Publishing becarispublishing.com/digital-cont...

New real-world data platform launched to support Alzheimer’s research | Becaris Publishing

New real-world data platform launched to support Alzheimer’s research | Becaris Publishing becarispublishing.com/digital-cont...

Your guide to the World Evidence, Pricing and Access Congress 2026: Key sessions on RWE, AI, launch strategies, rare diseases and patient centricity becarispublishing.com/digital-cont...

Your guide to the World Evidence, Pricing and Access Congress 2026: Key sessions on pricing, EU HTA, innovation and sustainability | Becaris Publishing

Your guide to the World Evidence, Pricing and Access Congress 2026: Key sessions on pricing, EU HTA, innovation and sustainability becarispublishing.com/digital-cont... #WorldEPACongress #MarketAccess #HTA

Market access and HTA developments with Sreeram Ramagopalan: US–UK policy updates and evolving US drug pricing reforms | Becaris Publishing

Market access and HTA developments with Sreeram Ramagopalan: US–UK policy updates and evolving US drug pricing reforms | Becaris Publishing becarispublishing.com/digital-cont...

ISPOR’s Laura Pizzi and Mitch Higashi on the 2026–2027 Top 10 HEOR Trends and their implications for evidence and access | Becaris Publishing

ISPOR’s Laura Pizzi and Mitch Higashi on the 2026–2027 Top 10 HEOR Trends and their implications for evidence and access @ispor.bsky.social becarispublishing.com/digital-cont...

Gamechanger for UK research as NHS England advances consented GP data access | Becaris Publishing

Gamechanger for UK research as NHS England advances consented GP data access | Becaris Publishing becarispublishing.com/digital-cont...

Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospec... Aim: To compare oral corticosteroid (OCS) burden and healthcare resource utilization (HCRU) in patients with chronic rhinosinusitis with nasal polyps undergoing functional endoscopic sinus surgery (FE...

📢New article alert

Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospective cohort study

🔗 becarispublishing.com/doi/10.57264...

#OpenAccess #JCER

Why misaligned evidence strategies delay patient access to medicines | Becaris Publishing

Why misaligned evidence strategies delay #PatientAccess to medicines | Becaris Publishing becarispublishing.com/digital-cont...

BC Platforms and OmicsBank launch collaboration to grow real-world and multi-omics evidence from India and the UAE | Becaris Publishing

BC Platforms and OmicsBank launch collaboration to grow real-world and multi-omics evidence from India and the UAE | Becaris Publishing becarispublishing.com/digital-cont...

TrumpRx launches to lower US drug prices, but early reaction is mixed | Becaris Publishing

TrumpRx launches to lower US drug prices, but early reaction is mixed | Becaris Publishing becarispublishing.com/digital-cont... #DrugPricing #MFN #MostFavoredNation #MarketAccess

Rare disease outcome assessment under EU HTA and joint clinical assessment | Becaris Publishing

#RareDisease outcome assessment under #EUHTA and #JointClinicalAssessment | Becaris Publishing becarispublishing.com/digital-cont...

Hot off the press: Part one of our pick of articles within HTA and RWE published in January 2026 | Becaris Publishing

Hot off the press: Part one of our pick of articles within #HTA and #RWE published in January 2026 | Becaris Publishing becarispublishing.com/digital-cont...

Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial External comparator (EC) studies can improve identification of compounds with the most promising performance in pre-pivotal single-arm trials (SAT). As SAT output lacks comparative insights, EC studie...

📢New article alert

New Perspective article on "Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial"

🔗Read here: becarispublishing.com/doi/10.57264...

#OpenAccess #JCER #TrialMethodology #RealWorldEvidence #RWE

Head-to-head real-world study reports overall survival advantage with apalutamide compared with darolutamide in metastatic castration-sensitive prostate cancer | Becaris Publishing

Head-to-head real-world study reports overall survival advantage with apalutamide compared with darolutamide in metastatic castration-sensitive #ProstateCancer | Becaris Publishing becarispublishing.com/digital-cont...

Industry update tracker: January 2026 | Becaris Publishing

#IndustryUpdate tracker: January 2026 | Becaris Publishing becarispublishing.com/digital-cont...

Patient roles and expectations in effective HTA engagement | Becaris Publishing

Patient roles and expectations in effective #HTA engagement | Becaris Publishing becarispublishing.com/digital-cont...

Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer Aim: In the single-arm MOUNTAINEER trial (NCT03043313) tucatinib in combination with trastuzumab showed an objective response rate (ORR) of 39.3% in patients with previously treated, HER2+ unresectabl...

📢New article alert

New Research Article on “Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2–positive metastatic colorectal cancer”.

🔗Read here: becarispublishing.com/doi/10.57264...

#OpenAccess #JCER #ColorectalCancer #Oncology #ITC

CMS announces drugs selected for third cycle of Medicare drug price negotiations | Becaris Publishing

#CMS announces drugs selected for third cycle of #Medicare #DrugPrice negotiations | Becaris Publishing becarispublishing.com/digital-cont...

Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective Aim: Proteinuria poses a significant challenge in focal segmental glomerulosclerosis (FSGS), particularly when resistant to standard treatments. Acthar® Gel, a Food and Drug Administration (FDA)-appro...

📢New Research Article alert

"Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective"

🔗 becarispublishing.com/doi/10.57264...

#OpenAccess #JCER #KidneyDisease

Modeling caregiver quality of life in HTA: Why economic models struggle to reflect lived experience | Becaris Publishing

Modeling #caregiver quality of life in #HTA: Why economic models struggle to reflect lived experience | Becaris Publishing becarispublishing.com/digital-cont...

First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis Aim: To compare characteristics of patients with anticitrullinated protein antibody-positive (ACPA+) and rheumatoid factor-positive (RF+) rheumatoid arthritis (RA) who initiated abatacept or a tumor n...

📢New article alert

New Short Report on "First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis".

🔗Read here: becarispublishing.com/doi/10.57264...

#OpenAccess

New in the Journal of Comparative Effectiveness Research: Video Snapshots | Becaris Publishing

New in the Journal of Comparative Effectiveness Research: Video Snapshots | Becaris Publishing becarispublishing.com/digital-cont...